Beyond Air (XAIR) Competitors

Beyond Air (NASDAQ:XAIR) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Do institutionals & insiders hold more shares of XAIR or CTSO?

31.5% of Beyond Air shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 19.4% of Beyond Air shares are held by insiders. Comparatively, 7.3% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has better earnings & valuation, XAIR or CTSO?

Cytosorbents has higher revenue and earnings than Beyond Air. Cytosorbents is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beyond Air	$3.70M	4.03	-$46.62M	-$0.79	-0.22
Cytosorbents	$35.60M	1.86	-$20.72M	-$0.28	-3.79

Is XAIR or CTSO more profitable?

Cytosorbents has a net margin of -41.77% compared to Beyond Air's net margin of -1,258.46%. Cytosorbents' return on equity of -105.04% beat Beyond Air's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beyond Air	-1,258.46%	-233.96%	-113.92%
Cytosorbents	-41.77%	-105.04%	-29.18%

Do analysts rate XAIR or CTSO?

Beyond Air presently has a consensus target price of $1.50, suggesting a potential upside of 769.06%. Cytosorbents has a consensus target price of $5.50, suggesting a potential upside of 418.87%. Given Beyond Air's stronger consensus rating and higher possible upside, equities research analysts clearly believe Beyond Air is more favorable than Cytosorbents.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beyond Air	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Cytosorbents	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more risk and volatility, XAIR or CTSO?

Beyond Air has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.

Does the media prefer XAIR or CTSO?

In the previous week, Beyond Air and Beyond Air both had 3 articles in the media. Beyond Air's average media sentiment score of 1.07 beat Cytosorbents' score of 0.67 indicating that Beyond Air is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beyond Air	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cytosorbents beats Beyond Air on 8 of the 15 factors compared between the two stocks.